Brian Swint
Positive results from clinical trials often give biotechnology companies a boost, but this one was big.
Shares of Sana Biotechnology -- a firm with a market capitalization of less than $400 million as of Tuesday's close -- surged 333% when the market opened to $7.17. It announced clinical results for an in-human study on a Type 1 diabetes treatment that it says are positive. The treatment uses cell transplantation to help the body produce its own insulin.
The stock could soar even higher. Before the results were announced, the average target price among three analysts surveyed by FactSet was $10. Analysts at TD Cowen led by Marc Frahm upgraded the shares to Buy from Hold, though they don't have a price target.
"Today's data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with Type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible," said Per-Ola Carlsson, who led the study at Uppsala University Hospital.
The swings aren't particularly unusual for Sana, which was founded in 2018 and is based in Seattle. It's now on track to close around the level last seen in August last year, and it's still down 87% from a high reached in 2021.
Write to Brian Swint at brian.swint@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 08, 2025 10:11 ET (15:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。